These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26611245)

  • 41. Paranasal sinusitis after long-term use of topical nasal decongestants.
    Min YG; Kim HS; Suh SH; Jeon SY; Son YI; Yoon S
    Acta Otolaryngol; 1996 May; 116(3):465-71. PubMed ID: 8790749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Superficial nasal mucosal blood flow and nasal patency following topical oxymetazoline hydrochloride.
    Witek TJ; Canestrari DA; Hernandez JR; Miller RD; Yang JY; Riker DK
    Ann Allergy; 1992 Feb; 68(2):165-8. PubMed ID: 1739191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-masked, randomized, placebo-controlled study to evaluate the efficacy and tolerability of intranasal K305 (3% tetracaine plus 0.05% oxymetazoline) in anesthetizing maxillary teeth.
    Hersh EV; Pinto A; Saraghi M; Saleh N; Pulaski L; Gordon SM; Barnes D; Kaplowitz G; Bloom I; Sabti M; Moore PA; Lee S; Meharry M; He DY; Li Y
    J Am Dent Assoc; 2016 Apr; 147(4):278-87. PubMed ID: 26822100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers.
    Graf P; Hallén H; Juto JE
    Clin Exp Allergy; 1995 May; 25(5):395-400. PubMed ID: 7553241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of intranasal challenge with interleukin-6 on upper airway symptomatology and physiology in allergic and nonallergic patients.
    Gentile DA; Yokitis J; Angelini BL; Doyle WJ; Skoner DP
    Ann Allergy Asthma Immunol; 2001 May; 86(5):531-6. PubMed ID: 11379804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.
    Graf P
    Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histamine sensitivity in the nasal mucosa during four-week use of oxymetazoline.
    Graf P; Juto JE
    Rhinology; 1994 Sep; 32(3):123-6. PubMed ID: 7839081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time-dependent middle ear pressure changes under general anaesthesia in children: N2O-O2 mixture versus air-oxygen mixture.
    Apan A; Muluk NB; Güler S; Budak B
    B-ENT; 2013; 9(2):141-50. PubMed ID: 23909121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging.
    Pritchard S; Glover M; Guthrie G; Brum J; Ramsey D; Kappler G; Thomas P; Stuart S; Hull D; Gowland P
    Pulm Pharmacol Ther; 2014 Feb; 27(1):121-6. PubMed ID: 23988443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of oxymetazoline on nasal and sinus mucosal blood flow in the rabbit as measured with laser-Doppler flowmetry.
    Akerlund A; Arfors KE; Bende M; Intaglietta M
    Ann Otol Rhinol Laryngol; 1993 Feb; 102(2):123-6. PubMed ID: 8427497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of middle ear barotrauma with oxymetazoline/fluticasone treatment.
    Millan SB; Hontz-Geisinger CA; Rooks BJ; Wahl AM; Covington DB
    Undersea Hyperb Med; 2021; 48(2):149-152. PubMed ID: 33975404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal.
    Graf PM; Hallén H
    Am J Rhinol; 1997; 11(1):67-72. PubMed ID: 9065350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults.
    Taverner D; Bickford L; Shakib S; Tonkin A
    Eur J Clin Pharmacol; 1999 Sep; 55(7):509-13. PubMed ID: 10501820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.
    Tas A; Yagiz R; Yalcin O; Uzun C; Huseyinova G; Adali MK; Karasalihoglu AR
    Otolaryngol Head Neck Surg; 2005 Apr; 132(4):608-12. PubMed ID: 15806055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topical nasal anesthesia and laryngopharyngeal sensory testing: a prospective, double-blind crossover study.
    Johnson PE; Belafsky PC; Postma GN
    Ann Otol Rhinol Laryngol; 2003 Jan; 112(1):14-6. PubMed ID: 12537052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
    Vaidyanathan S; Williamson P; Clearie K; Khan F; Lipworth B
    Am J Respir Crit Care Med; 2010 Jul; 182(1):19-24. PubMed ID: 20203244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.
    Neighbors CL; Salvador CF; Zhu B; Camacho M; Tsai P
    J Laryngol Otol; 2022 Jan; 136(1):8-16. PubMed ID: 34702392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute coronary syndrome after nasal spray of oxymetazoline.
    Montastruc F; Montastruc G; Taudou MJ; Olivier-Abbal P; Montastruc JL; Bondon-Guitton E
    Chest; 2014 Dec; 146(6):e214-e215. PubMed ID: 25451367
    [No Abstract]   [Full Text] [Related]  

  • 59. Middle ear pressure variations during 50% N2O anesthesia as a function of mastoid pneumatization.
    Elam M; Harell M; Luntz M; Fuchs C; Sadé J
    Am J Otol; 1998 Nov; 19(6):709-11. PubMed ID: 9831141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nasal airway resistance after decongestion with a nasal spray or a bellows device.
    Jessen M; Ivarsson A; Malm L
    Rhinology; 1996 Mar; 34(1):28-31. PubMed ID: 8739865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.